The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Elizabeth Barrett named CEO of Novartis Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Elizabeth Barrett was appointed CEO Novartis Oncology and a member of the executive committee of Novartis.

Barrett is currently Global President Oncology at Pfizer Inc.

Barrett succeeds Bruno Strigini who is retiring from Novartis for personal reasons, the company said.

Barrett’s appointment is effective Feb. 1, and she will be based in Basel.

In her most recent role at Pfizer, Barrett led the oncology business through a significant period of growth achieved in less than three years. Before joining Pfizer in 2009, she worked at Cephalon Inc. and Johnson & Johnson. She started her career at Kraft Foods Group Inc. in 1984.

Novartis also announced today that Robert Kowalski, head of global regulatory affairs, will assume ad interim leadership of the drug development organization effective Feb. 1. Kowalski has been head of global regulatory affairs for Novartis since February 2016 and has played an important leadership role in securing approvals for several breakthrough medicines including our revolutionary CAR-T therapy Kymriah, the company said.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
By W. Kimryn Rathmell

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account